A severe form of leishmaniasis characterized by irregular bouts of fever, substantial weight loss, swelling of the spleen and liver, and anemia (which may be serious). If left untreated it may lead to...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for visceral leishmaniasis is limited primarily because it affects fewer than 200,000 people annually in the United States, resulting in fewer systematic clinical studies. Additionally, the complexity of the disease and its symptoms can overlap with other conditions, making characterization difficult. As research continues, there is hope for better understanding and treatment options.
To navigate your care for visceral leishmaniasis, consider seeking a specialist in infectious diseases with experience in tropical diseases. Engaging with clinical trials may provide access to new treatments, so inquire about eligibility at your next appointment. Additionally, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support and information. While no specific patient organizations are identified, participating in clinical trials can also contribute to the understanding of this disease.
There are several orphan drugs designated for visceral leishmaniasis, including Aminosidine, amphotericin B, and corifungin, which are currently in development. Additionally, there are 8 active clinical trials exploring various aspects of treatment and management. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=visceral%20leishmaniasis.
Actionable guidance for navigating care for visceral leishmaniasis
To navigate your care for visceral leishmaniasis, consider seeking a specialist in infectious diseases with experience in tropical diseases. Engaging with clinical trials may provide access to new treatments, so inquire about eligibility at your next appointment. Additionally, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support and information. While no specific patient organizations are identified, participating in clinical trials can also contribute to the understanding of this disease.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for visceral leishmaniasis is limited primarily because it affects fewer than 200,000 people annually in the United States, resulting in fewer systematic clinical studies. Additionally, the complexity of the disease and its symptoms can overlap with other conditions, making characterization difficult. As research continues, there is hope for better understanding and treatment options.
To navigate your care for visceral leishmaniasis, consider seeking a specialist in infectious diseases with experience in tropical diseases. Engaging with clinical trials may provide access to new treatments, so inquire about eligibility at your next appointment. Additionally, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support and information. While no specific patient organizations are identified, participating in clinical trials can also contribute to the understanding of this disease.
There are several orphan drugs designated for visceral leishmaniasis, including Aminosidine, amphotericin B, and corifungin, which are currently in development. Additionally, there are 8 active clinical trials exploring various aspects of treatment and management. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=visceral%20leishmaniasis.
Actionable guidance for navigating care for visceral leishmaniasis
To navigate your care for visceral leishmaniasis, consider seeking a specialist in infectious diseases with experience in tropical diseases. Engaging with clinical trials may provide access to new treatments, so inquire about eligibility at your next appointment. Additionally, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support and information. While no specific patient organizations are identified, participating in clinical trials can also contribute to the understanding of this disease.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for visceral leishmaniasis is limited primarily because it affects fewer than 200,000 people annually in the United States, resulting in fewer systematic clinical studies. Additionally, the complexity of the disease and its symptoms can overlap with other conditions, making characterization difficult. As research continues, there is hope for better understanding and treatment options.
To navigate your care for visceral leishmaniasis, consider seeking a specialist in infectious diseases with experience in tropical diseases. Engaging with clinical trials may provide access to new treatments, so inquire about eligibility at your next appointment. Additionally, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support and information. While no specific patient organizations are identified, participating in clinical trials can also contribute to the understanding of this disease.
There are several orphan drugs designated for visceral leishmaniasis, including Aminosidine, amphotericin B, and corifungin, which are currently in development. Additionally, there are 8 active clinical trials exploring various aspects of treatment and management. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=visceral%20leishmaniasis.
Actionable guidance for navigating care for visceral leishmaniasis
To navigate your care for visceral leishmaniasis, consider seeking a specialist in infectious diseases with experience in tropical diseases. Engaging with clinical trials may provide access to new treatments, so inquire about eligibility at your next appointment. Additionally, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support and information. While no specific patient organizations are identified, participating in clinical trials can also contribute to the understanding of this disease.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 8 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.